Eric Siemers Sells 6,834 Shares of Acumen Pharmaceuticals (NASDAQ:ABOS) Stock

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) insider Eric Siemers sold 6,834 shares of Acumen Pharmaceuticals stock in a transaction on Tuesday, January 6th. The shares were sold at an average price of $1.97, for a total value of $13,462.98. Following the transaction, the insider directly owned 159,464 shares of the company’s stock, valued at approximately $314,144.08. The trade was a 4.11% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Eric Siemers also recently made the following trade(s):

• On Monday, January 5th, Eric Siemers sold 4,000 shares of Acumen Pharmaceuticals stock. The stock was sold at an average price of $1.96, for a total transaction of $7,840.00.

Acumen Pharmaceuticals Trading Down 6.5%

Shares of ABOS stock opened at $1.86 on Friday. The company has a market capitalization of $112.66 million, a P/E ratio of -0.84 and a beta of 0.23. Acumen Pharmaceuticals, Inc. has a 12-month low of $0.86 and a 12-month high of $2.46. The company has a quick ratio of 6.02, a current ratio of 6.02 and a debt-to-equity ratio of 0.29. The firm has a 50-day moving average price of $1.95 and a 200 day moving average price of $1.68.

Acumen Pharmaceuticals (NASDAQ:ABOS) last issued its quarterly earnings data on Wednesday, November 12th. The company reported ($0.44) earnings per share for the quarter, topping the consensus estimate of ($0.63) by $0.19. Research analysts forecast that Acumen Pharmaceuticals, Inc. will post -1.56 earnings per share for the current fiscal year.

Key Stories Impacting Acumen Pharmaceuticals

Here are the key news stories impacting Acumen Pharmaceuticals this week:

• Positive Sentiment: Recent quarterly results showed an EPS beat (reported -$0.44 vs. consensus -$0.63), evidence management has been narrowing losses versus expectations. MarketBeat ABOS page
• Positive Sentiment: Analyst coverage remains tilted toward buys — MarketBeat notes a “Moderate Buy” consensus and a blended target (~$6.75), which could support upside if clinical progress continues.
• Neutral Sentiment: Institutional ownership is high (~71%) and several funds have recently added small/new positions — this can increase liquidity but also correlate with larger block moves.
• Neutral Sentiment: Trading activity has been elevated versus the stock’s average volume (recent session ~588k vs. avg ~260k), indicating stronger investor response to the filings and news flow. Market activity
• Negative Sentiment: CEO Daniel J. O’Connell sold large blocks (three trades Jan. 5–7 totaling ~47,506 shares; the biggest single-day sale was ~37,755 shares on Jan. 7), trimming his stake by ~5.7% and raising about $75k on the largest sale — a sizable insider reduction that can be perceived as negative. SEC Filing
• Negative Sentiment: CFO Matt Zuga executed multiple sales across Jan. 5–7 (totaling ~14,905 shares), reducing his holdings by low-single-digit percentages and raising roughly $29k — further insider selling pressure. SEC Filing
• Negative Sentiment: COO Russell Barton sold several tranches (Jan. 5–7 totaling ~9,318 shares), trimming his stake and raising about $18k — adds to the cluster of executive selling. SEC Filing
• Negative Sentiment: Insider Eric Siemers sold multiple tranches (Jan. 5–6 totaling 10,834 shares), a further reduction of insider holdings and incremental supply to the market. SEC Filing

Institutional Trading of Acumen Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Jacobs Levy Equity Management Inc. acquired a new position in Acumen Pharmaceuticals during the 3rd quarter valued at about $27,000. Marex Group plc bought a new stake in shares of Acumen Pharmaceuticals during the second quarter worth approximately $39,000. Qube Research & Technologies Ltd lifted its holdings in Acumen Pharmaceuticals by 160.0% in the second quarter. Qube Research & Technologies Ltd now owns 57,559 shares of the company’s stock valued at $67,000 after buying an additional 35,424 shares during the period. AQR Capital Management LLC bought a new position in Acumen Pharmaceuticals in the first quarter valued at approximately $46,000. Finally, Susquehanna International Group LLP boosted its stake in Acumen Pharmaceuticals by 26.5% in the third quarter. Susquehanna International Group LLP now owns 214,440 shares of the company’s stock valued at $367,000 after acquiring an additional 44,902 shares during the last quarter. 71.01% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of analysts have recently weighed in on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Acumen Pharmaceuticals in a research note on Tuesday, October 14th. Wall Street Zen raised shares of Acumen Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Sunday, December 21st. Finally, Bank of America dropped their target price on shares of Acumen Pharmaceuticals from $9.00 to $8.00 and set a “buy” rating for the company in a research note on Tuesday, November 18th. Four analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Acumen Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $6.75.

Acumen Pharmaceuticals Company Profile

Acumen Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of oral small molecule therapies for neurodegenerative diseases. Leveraging a proprietary drug discovery platform that integrates chemoproteomics, high-throughput screening and computational chemistry, the company seeks to identify and optimize compounds that selectively modulate pathological protein aggregation. Its approach is designed to address the underlying biology of conditions such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis and related proteinopathies.

The company’s pipeline comprises multiple lead candidates at various stages of preclinical and early clinical development.